Recurrent Oropharyngeal Squamous Cell Carcinoma Recruiting Phase 2 Trials for Cabozantinib (DB08875)

IndicationStatusPhase
DBCOND0037158 (Recurrent Oropharyngeal Squamous Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03468218Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based TherapyTreatment